Evidence map›Paper›PMID 30154657›Full record

ReviewInternational journal of nanomedicine2018

Recent advances in "smart" delivery systems for extended drug release in cancer therapy.

Regina-Veronicka Kalaydina, Komal Bajwa, Bessi Qorri, Alexandria Decarlo, Myron R Szewczuk

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Nanocarrier drug delivery systems for gynecological cancer therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Smart exosomes enhance PDAC targeted therapy.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
  18. Review
  19. Biomaterials for Drug Delivery and Human Applications.Materials (Basel, Switzerland) · 2024
    Review
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Regina-Veronicka KalaydinaDepartment of Biomedical and Molecular Sciences, Queen's University, szewczuk@queensu.ca.
Komal BajwaPostgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen's University.
Bessi QorriDepartment of Biomedical and Molecular Sciences, Queen's University, szewczuk@queensu.ca.
Alexandria DecarloDepartment of Biology, Queen's University, Kingston, ON, Canada.
Myron R SzewczukDepartment of Biomedical and Molecular Sciences, Queen's University, szewczuk@queensu.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in nanomedicine have become indispensable for targeted drug delivery, early detection, and increasingly personalized approaches to cancer treatment. Nanoparticle-based drug-delivery systems have overcome some of the limitations associated with traditional cancer-therapy administration, such as reduced drug solubility, chemoresistance, systemic toxicity, narrow therapeutic indices, and poor oral bioavailability. Advances in the field of nanomedicine include "smart" drug delivery, or multiple levels of targeting, and extended-release drug-delivery systems that provide additional methods of overcoming these limitations. More recently, the idea of combining smart drug delivery with extended-release has emerged in hopes of developing highly efficient nanoparticles with improved delivery, bioavailability, and safety profiles. Although functionalized and extended-release drug-delivery systems have been studied extensively, there remain gaps in the literature concerning their application in cancer treatment. We aim to provide an overview of smart and extended-release drug-delivery systems for the delivery of cancer therapies, as well as to introduce innovative advancements in nanoparticle design incorporating these principles. With the growing need for increasingly personalized medicine in cancer treatment, smart extended-release nanoparticles have the potential to enhance chemotherapy delivery, patient adherence, and treatment outcomes in cancer patients.

Indexed as

Drug LiberationPrecision MedicineAntineoplastic AgentsDrug Delivery SystemsHumansNanomedicineNanoparticlesNeoplasmsAntineoplastic Agentsextended drug releasenanomedicinepersonalized medicinesmart delivery systems

Identifiers

PMID30154657
PMCPMC6108334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.